Cargando…

Ferroptosis in cancer and cancer immunotherapy

The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lei, Zhou, Xiaoxue, Xie, Feng, Zhang, Lei, Yan, Haiyan, Huang, Jun, Zhang, Chong, Zhou, Fangfang, Chen, Jun, Zhang, Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822596/
https://www.ncbi.nlm.nih.gov/pubmed/35133083
http://dx.doi.org/10.1002/cac2.12250
_version_ 1784646630015762432
author Zhao, Lei
Zhou, Xiaoxue
Xie, Feng
Zhang, Lei
Yan, Haiyan
Huang, Jun
Zhang, Chong
Zhou, Fangfang
Chen, Jun
Zhang, Long
author_facet Zhao, Lei
Zhou, Xiaoxue
Xie, Feng
Zhang, Lei
Yan, Haiyan
Huang, Jun
Zhang, Chong
Zhou, Fangfang
Chen, Jun
Zhang, Long
author_sort Zhao, Lei
collection PubMed
description The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology, physiology and biochemistry. The broad spectrum of injury and tumor tolerance are the main reasons for radiotherapy and chemotherapy failure. The effective rate of tumor immunotherapy as a new treatment method is less than 30%. Ferroptosis can be seen in radiotherapy, chemotherapy, and tumor immunotherapy; therefore, ferroptosis activation may be a potential strategy to overcome the drug resistance mechanism of traditional cancer treatments. In this review, the characteristics and causes of cell death by lipid peroxidation in ferroptosis are briefly described. In addition, the three metabolic regulations of ferroptosis and its crosstalk with classical signaling pathways are summarized. Collectively, these findings suggest the vital role of ferroptosis in immunotherapy based on the interaction of ferroptosis with tumor immunotherapy, chemotherapy and radiotherapy, thus, indicating the remarkable potential of ferroptosis in cancer treatment.
format Online
Article
Text
id pubmed-8822596
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88225962022-02-11 Ferroptosis in cancer and cancer immunotherapy Zhao, Lei Zhou, Xiaoxue Xie, Feng Zhang, Lei Yan, Haiyan Huang, Jun Zhang, Chong Zhou, Fangfang Chen, Jun Zhang, Long Cancer Commun (Lond) Reviews The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology, physiology and biochemistry. The broad spectrum of injury and tumor tolerance are the main reasons for radiotherapy and chemotherapy failure. The effective rate of tumor immunotherapy as a new treatment method is less than 30%. Ferroptosis can be seen in radiotherapy, chemotherapy, and tumor immunotherapy; therefore, ferroptosis activation may be a potential strategy to overcome the drug resistance mechanism of traditional cancer treatments. In this review, the characteristics and causes of cell death by lipid peroxidation in ferroptosis are briefly described. In addition, the three metabolic regulations of ferroptosis and its crosstalk with classical signaling pathways are summarized. Collectively, these findings suggest the vital role of ferroptosis in immunotherapy based on the interaction of ferroptosis with tumor immunotherapy, chemotherapy and radiotherapy, thus, indicating the remarkable potential of ferroptosis in cancer treatment. John Wiley and Sons Inc. 2022-02-08 /pmc/articles/PMC8822596/ /pubmed/35133083 http://dx.doi.org/10.1002/cac2.12250 Text en © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Zhao, Lei
Zhou, Xiaoxue
Xie, Feng
Zhang, Lei
Yan, Haiyan
Huang, Jun
Zhang, Chong
Zhou, Fangfang
Chen, Jun
Zhang, Long
Ferroptosis in cancer and cancer immunotherapy
title Ferroptosis in cancer and cancer immunotherapy
title_full Ferroptosis in cancer and cancer immunotherapy
title_fullStr Ferroptosis in cancer and cancer immunotherapy
title_full_unstemmed Ferroptosis in cancer and cancer immunotherapy
title_short Ferroptosis in cancer and cancer immunotherapy
title_sort ferroptosis in cancer and cancer immunotherapy
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822596/
https://www.ncbi.nlm.nih.gov/pubmed/35133083
http://dx.doi.org/10.1002/cac2.12250
work_keys_str_mv AT zhaolei ferroptosisincancerandcancerimmunotherapy
AT zhouxiaoxue ferroptosisincancerandcancerimmunotherapy
AT xiefeng ferroptosisincancerandcancerimmunotherapy
AT zhanglei ferroptosisincancerandcancerimmunotherapy
AT yanhaiyan ferroptosisincancerandcancerimmunotherapy
AT huangjun ferroptosisincancerandcancerimmunotherapy
AT zhangchong ferroptosisincancerandcancerimmunotherapy
AT zhoufangfang ferroptosisincancerandcancerimmunotherapy
AT chenjun ferroptosisincancerandcancerimmunotherapy
AT zhanglong ferroptosisincancerandcancerimmunotherapy